COSTA MESA, Calif.--(BUSINESS WIRE)--Sept. 11, 2006--Valeant Pharmaceuticals International (NYSE:VRX) today announced that the Securities and Exchange Commission is conducting an informal inquiry regarding events and circumstances surrounding trading in the company’s common stock and the public release of data from its first pivotal Phase 3 trial for Viramidine(R). In addition, the SEC requested data regarding the company’s stock option grants since January 1, 2000 and information about the company’s pursuit in the Delaware Chancery Court of the return of bonuses paid to Milan Panic, the company’s former chairman and chief executive officer, and others, in connection with the Ribapharm initial public offering.
